Cartalax
- Category
- Bioregulators
- Administration routes
- InjectableOral
- Regulatory status
- Not FDA-approved
A synthetic tripeptide (Ala-Glu-Asp) marketed for joint and cartilage support, said to regulate genes in chondrocytes and osteoblasts tied to cartilage repair and bone formation. The case is mostly mechanistic and speculative, drawn from cell studies rather than human trials, so joint benefit claims remain unproven in people. There is essentially no human safety data, and supply is largely unregulated research-grade product. Not an approved drug in the US.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Cartalax is a synthetic three-amino-acid peptide (Ala-Glu-Asp) developed by the Khavinson group in Russia. Its sequence corresponds to a motif found in type XI collagen, a structural protein critical for cartilage integrity. It is designed to support cartilage and musculoskeletal tissue health by modulating gene expression in cartilage cells (chondrocytes) and connective tissue cells (fibroblasts).
How it works in the body
A bioregulator tripeptide (Ala-Glu-Asp) that targets cartilage and bone cells. It penetrates chondrocytes and osteoblasts to regulate gene expression involved in cartilage matrix production, bone mineralization, and the balance between tissue breakdown and repair.
Research overview
Molecular docking predicts AED binding to a DNA sequence; this has not established its mechanism inside cartilage cells. In cell studies, AED activated the expression of key genes involved in cartilage formation and maintenance — including SOX9 (the master regulator of cartilage development), aggrecan, type II collagen, and COMP — stimulated proliferation and regeneration markers, inhibited MMP-9, an enzyme that breaks down cartilage, and suppressed programmed cell death in aging connective tissue cells. Russian clinical experience reports benefits for patients with spinal disc disease, osteoarthritis, osteoporosis, and post-fracture recovery. However, large-scale Western clinical trials are absent — most evidence comes from lab studies and clinical observations from Russian medical practice, primarily from the Khavinson group. Independent validation and rigorous human trials are needed.
Who researches Cartalax?
Commonly researched by
People researching bone health and density
Studied for effects on bone mineralization, fracture healing, or osteoporosis.
People researching chondrogenic gene activation
One of the primary studied benefits of Cartalax.
Important considerations for
Those who are pregnant or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Anyone under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Those with Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Safety & interactions
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(5)
Rated by level of concern
Lack of large-scale clinical safety data
HighClinicalTrials.gov - no records; PubMed - no human safety studies indexed
Mild injection site reactions
LowClass-level expectation for subcutaneous peptide injection; no AED-specific data
Potential allergic reactions
LowMechanistic reasoning from peptide size/composition; no reported AED hypersensitivity cases in the literature
Unregulated product quality
HighNo FDA approval or DMF; no compendial monograph
Unknown long-term effects
ModeratePMID 32399807 (NFkB, IGF1, TERT, TNKS2 modulation in FetMSC aging cultures); no chronic toxicology available
Interaction summary(8)
Rated by direction with this peptide
Intra-articular corticosteroids (triamcinolone, methylprednisolone)
CautionTheoreticalRepeated intra-articular corticosteroids are catabolic to cartilage and suppress chondrocyte matrix synthesis, which would work directly against AED's proposed anabolic/anti-apoptotic effect on connective tissue, so any benefit signal from concurrent use is likely blunted or confounded. This is mechanistic opposition, not a documented drug interaction.
Mechanistic opposition; corticosteroid effects on cartilage are documented in humans (McAlindon et al., JAMA 2017, intra-articular triamcinolone vs saline - greater cartilage volume loss). No AED-specific interaction study exists.
NSAIDs (ibuprofen, naproxen, celecoxib)
NeutralTheoreticalNo shared metabolic or transport pathway is plausible for a three-residue peptide cleared by peptidases, but NSAID analgesia will mask joint symptoms and make any self-assessed response to Cartalax uninterpretable.
Mechanistic reasoning; no documented pharmacokinetic interaction
Anticoagulants and antiplatelets (warfarin, apixaban, clopidogrel, aspirin)
CautionLowPurely a route-of-administration issue: subcutaneous injection in an anticoagulated person carries a higher risk of bruising and hematoma at the injection site, with no pharmacologic interaction with the peptide itself.
Class-level subcutaneous injection risk; no AED pharmacodynamic interaction reported
Growth hormone / IGF-1 axis agents (somatropin, tesamorelin, IGF-1 analogues)
CautionTheoreticalAED increased IGF1 gene expression in human mesenchymal stem cell aging cultures (3.5-5.6 fold), so using it with agents that already raise systemic IGF-1 adds to a push on a proliferative axis. This is in vitro transcript data only - no systemic IGF-1 elevation has been demonstrated in any animal or human, and the combination has never been studied.
PMID 32399807 (AED increases IGF1 expression in human MSC cultures)
Immunosuppressants and biologic DMARDs (methotrexate, TNF inhibitors, JAK inhibitors)
CautionTheoreticalAED was among the peptides that modulated NFkB gene expression in human MSC aging cultures - a pro-inflammatory transcription factor whose suppression is the therapeutic goal of these drugs - raising a theoretical possibility of pharmacodynamic opposition in inflammatory arthritis. The direction and magnitude of the AED-specific NFkB effect are not cleanly established, and nothing has been shown at the protein or clinical level.
PMID 32399807 (NFkB among genes modulated by the studied peptides in MSC cultures; AED-specific direction not clearly isolated)
Tetracyclines with MMP-inhibiting activity (doxycycline)
SynergisticTheoreticalDoxycycline inhibits MMP enzymatic activity and AED reduced MMP-9 synthesis in aging fibroblasts, so the two act on the same matrix-degradation pathway at different levels (activity vs synthesis) and would be expected to be additive rather than antagonistic. Inferred additivity only - the combination has never been tested in any model.
PMID 27259496 (AED among peptides reducing MMP-9 synthesis); doxycycline MMP inhibition is established pharmacology; no combination study
Glucosamine / chondroitin sulfate and collagen peptides
NeutralTheoreticalThese supply matrix substrate while AED is proposed to act on the transcriptional side of matrix turnover. The complementarity is a hypothesis rather than an observed effect - no combination has been studied in any model, so no synergy should be assumed. No known safety concern either.
Mechanistic hypothesis only; no combination study exists
Other Khavinson bioregulator peptides (KE, KED, AEDG)
NeutralTheoreticalStudied side by side in the same culture models without reported antagonism, though every published comparison tested them in parallel rather than together, and no pharmacology or safety data exists for using any of them with AED.
PMID 27259496; PMID 32399807 (peptides tested in parallel, not in combination)
Known risks(5)
Lack of large-scale clinical safety data
No Phase I/II/III clinical trials in Western regulatory frameworks. Safety profile is based on Russian clinical experience and in vitro studies only.
Mild injection site reactions
If administered subcutaneously, mild redness, swelling, or irritation at the injection site may occur. Generally reported as transient.
Potential allergic reactions
As with any peptide, hypersensitivity reactions are theoretically possible, though not commonly reported with this small tripeptide.
Unregulated product quality
Cartalax is not FDA-approved, so FDA approval provides no assurance of its product purity or quality. Unregulated products sold online vary in purity.
Unknown long-term effects
Long-term safety of repeated use has not been studied in controlled trials. Effects of chronic gene expression modulation in cartilage tissue are not fully characterized.
Drug interactions(4)
NSAIDs / Corticosteroids
No documented interactions. However, since Cartalax modulates cartilage gene expression rather than inflammation directly, co-administration with anti-inflammatory drugs is theoretically compatible but unstudied in controlled settings.
Other Khavinson peptides
Often used with other bioregulator peptides in Russian practice (e.g., with Sigumir for comprehensive joint support). No adverse interactions reported, but formal interaction studies are lacking.
Immunosuppressants
Theoretical concern: since Cartalax modulates gene expression and cell proliferation markers (Ki-67), caution is warranted with immunosuppressive drugs. No formal interaction data available.
General note
No formal drug interaction studies have been conducted for Cartalax. As a tripeptide rapidly broken down to amino acids, significant pharmacokinetic interactions are considered unlikely but unproven.
Research & benefits
Evidence base
- Evidence Level
- Preclinical
- Total Studies
- 5
- Human Studies
- 0
LIMITED. Evidence is primarily preclinical (in vitro cell culture studies). No large-scale randomized controlled trials in Western literature. Key evidence: (1) In vitro: AED at 200 ng/ml activates chondrogenic differentiation markers in aging human MSCs (Myakisheva et al., 2023). (2) In vitro: AED inhibits MMP-9 and caspase-3 while upregulating Ki-67 and CD98hc in aging skin fibroblasts (Linkova et al., 2016). (3) Molecular modeling: AED binds ACCT DNA sequence, providing mechanistic basis (Khavinson et al., 2016). (4) Systematic review confirms short peptides including AED regulate gene expression via DNA-peptide interactions (Khavinson et al., 2021). Russian clinical experience reports benefits in musculoskeletal conditions but lacks peer-reviewed controlled trial data accessible in Western databases.
Researched for(6)
Rated by confidence in the evidence
Chondrogenic gene activation
SpeculativeAn indexed 2023 study found increased chondrogenic markers in aging human MSC cultures; clinical benefit remains unproven (PMID 37782646).
PMID 37782646: primary chondrogenic-marker experiment. PMID 37176122: review discussing AED in section 5 and Table 1.
Anti-apoptotic effects in connective tissue
LowReduced apoptosis markers in human skin fibroblasts and rat kidney explants, not cartilage.
PMID 27259496; PMID 26033601
Extracellular matrix protection
LowSingle in vitro study found MMP-9 suppression in aging skin fibroblasts, not cartilage.
PMID 27259496 (MMP-9 inhibition in aging skin fibroblasts)
Joint and cartilage support (clinical observations)
SpeculativeNo registered trials or indexed human joint studies; cited observations remain unverified.
No ClinicalTrials.gov record; no indexed human trial
Epigenetic gene regulation
SpeculativeGene expression shifts are documented, but no epigenetic mechanism has been shown for AED.
PMID 22708439 (Adv Gerontol 2012, general model, not AED-specific); PMID 35457077 (IJMS 2022 - does not include AED); PMID 32399807 (AED expression effects)
Cartilage matrix protein upregulation
SpeculativeA 2023 human MSC experiment measured increased cartilage-related proteins; it did not demonstrate repair of intact cartilage.
PMID 37782646: cartilage-related protein measurements in human MSC cultures. The type XI collagen sequence claim remains unverified.
Benefits(6)
Chondrogenic gene activation
Anti-apoptotic effects in connective tissue
Extracellular matrix protection
Joint and cartilage support (clinical observations)
Epigenetic gene regulation
Cartilage matrix protein upregulation
Key studies(5)
Myakisheva SN, Linkova NS, Diatlova AS, Polyakova VO, Ryzhak GA
Advances in Gerontology
2023
AED peptide at 200 ng/ml activates gene expression and protein synthesis of chondrogenic differentiation markers (SOX9, aggrecan, type II collagen, COMP) in human mesenchymal stem cells during replicative aging
Linkova N, Khavinson V, Diatlova A, Myakisheva S, Ryzhak G
International Journal of Molecular Sciences
2023
Review identifying peptides derived from growth factors and cartilage matrix components that regulate WNT, ERK-p38, and Smad 1/5/8 signaling pathways, gene expression of COL2, SOX9, ACAN for chondrogenic differentiation
Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR
Molecules
2021
Systematic review confirming AED (Cartalax) regulates cartilage and skin fibroblast functions. Short peptides penetrate nuclei, interact with nucleosomes, histones, and DNA to regulate gene expression
Lin'kova NS, Drobintseva AO, Orlova OA, Kuznetsova EP, Polyakova VO, Kvetnoy IM, Khavinson VKh
Bulletin of Experimental Biology and Medicine
2016
AED peptide inhibits MMP-9 synthesis, enhances Ki-67 and CD98hc expression, and suppresses caspase-dependent apoptosis in aging skin fibroblasts
Khavinson VKh, Lin'kova NS, Tarnovskaya SI
Bulletin of Experimental Biology and Medicine
2016
Molecular docking study showing AED peptide binds to ACCT DNA sequence. One short peptide can regulate dozens of genes through specific DNA-peptide interactions
Regulation & availability
Why researchers look at it
Increased chondrogenic markers in aging human MSC cultures. Separately, reduced MMP-9 synthesis in aging skin fibroblasts. Used in Russian clinical practice for osteoarthritis and spinal disc disease, though these applications lack controlled trial data in Western databases. If Western research groups validate its gene-regulatory effects, Cartalax could become relevant to the growing effort to develop disease-modifying osteoarthritis treatments.
- Estimated cost
- $30-80/mo oral capsules
- FDA status
- Cartalax is not FDA-approved and is not eligible for compounding in the US. Lack of FDA approval does not exempt a therapeutic product from FDA drug regulation. In Russia, Cartalax is part of the Khavinson bioregulator system used in clinical practice but does not hold Western regulatory approval.
- WADA status
- Not individually named in the 2026 list. S0 prohibits pharmacological substances without governmental approval for human therapeutic use. Peptide identity alone does not establish S2 classification.
- Prescribability
- Research only (March 2026). Not FDA-approved. Not available by prescription in the US or EU.
- Availability
- Not available by prescription.
International status
EU
Not approved
US
Not approved
Russia
Used clinically (Khavinson bioregulator protocol)
Worldwide
Limited to Russian clinical use
Regulatory timeline(6)
- 1990s-2000sDevelopment by Prof. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology as part of the Cytogens synthesized peptide bioregulator program
- 2003-2010Clinical use established in Russian medicine for musculoskeletal conditions. Cartalax registered as a bioregulator supplement in Russia
- 2016Key publications: Linkova et al. demonstrate AED effects on fibroblast aging markers; Khavinson et al. establish AED-DNA binding via molecular docking
- 2021Khavinson et al. publish systematic review in Molecules confirming AED/Cartalax role in cartilage and fibroblast gene regulation (PMID: 34834147)
- 2023Myakisheva et al. publish chondrogenic differentiation study showing AED activates cartilage markers in aging MSCs (PMID: 37782646). Linkova & Khavinson review peptide regulation of chondrogenic differentiation (PMID: 37176122)
- 2026 (current)No FDA approval identified. IND status cannot be established from public records alone; FDA generally keeps IND existence confidential. No Western clinical trials are registered on ClinicalTrials.gov.
Sources & FAQs
Research sources(6)
Frequently asked questions(4)
What is Cartalax?
Cartalax is a synthetic tripeptide (Ala-Glu-Asp / AED) bioregulator developed by Prof. Vladimir Khavinson. It is designed to normalize cartilage and musculoskeletal tissue function by modulating gene expression in chondrocytes and fibroblasts.
How does Cartalax work?
Molecular docking predicts that AED can bind an ACCT DNA sequence; binding inside cartilage cells was not demonstrated by that study. In cell studies, AED was reported to upregulate genes for cartilage matrix proteins (collagen type II, aggrecan, SOX9) and downregulate degradative enzymes (MMP-9) and apoptosis markers (caspase-3). The cited H1/H2B/H3/H4 binding experiment tested other short peptides rather than AED.
Is Cartalax FDA-approved?
No. Cartalax is not FDA-approved. IND existence is generally confidential, so a public-record search cannot establish that no IND was filed.
What is the difference between Cartalax and other Khavinson peptides?
Cartalax (AED) is cartilage-specific. Other Khavinson peptides target different tissues: Epithalon (AEDG) targets pineal/telomerase, Vesugen (KED) targets blood vessels, Bronchogen (AEDL) targets bronchial tissue, and Vilon (KE) targets immune function. They share the same gene-regulatory mechanism but differ in tissue specificity.